Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Twist Bioscience
TWST
Twist Bioscience
DNA Synthesis Commoditization And Trade Tensions Will Erode Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
06 Aug 25
Updated
06 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$25.00
9.8% overvalued
intrinsic discount
06 Aug
US$27.45
Loading
1Y
-38.4%
7D
-0.3%
Author's Valuation
US$25.0
9.8% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$25.0
9.8% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-220m
554m
2016
2018
2020
2022
2024
2025
2026
2028
Revenue US$553.8m
Earnings US$76.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
14.92%
Biotech revenue growth rate
11.40%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$76.35m
Earnings '28
x
26.31x
PE Ratio '28
=
US$2.01b
Market Cap '28
US$2.01b
Market Cap '28
/
66.02m
No. shares '28
=
US$30.43
Share Price '28
US$30.43
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$24.99
Fair Value '25
